The first therapy that uses gene-editing is to be offered on the NHS in a “revolutionary breakthrough” for patients. It will ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

In international clinical trials, 93 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment, with hopes that it could bring a ...

The FDA is currently reviewing beti-cel – also known as Zynteglo (betibeglogene autotemcel) – as a treatment for patients with beta thalassaemia who require regular blood transfusions.

People with beta thalassaemia do not produce enough haemoglobin, which is used by red blood cells to carry oxygen around the body. Patients with beta thalassemia often need a blood transfusion ...

“The war we’re in right now is much harder,” said Arab, who heads the Iranian Thalassaemia Society, which represent those with the blood disorder. “Innocent people are dying, not because ...

There is a need for a new strategic plan for blood donation, Miltos Miltiadou, president of the Pancyprian Thalassaemia ...

The health system has been decimated. Although violence has fallen, emergency funding is still well short of needs. Sharmila ...

Work at the Midlands Metropolitan University Hospital in Smethwick is nearly complete, with its doors set to open on Sunday, ...

The girl was enrolled in a KKH programme called Bridges, or Bringing Research Innovations for the Diagnosis of Genetic ...

It will be used as a potential cure for the blood disorder beta thalassaemia. Stem cells which make blood will be extracted, reprogrammed to correct the condition and returned to the patient's body.